Viatris Inc.

The investment case for Viatris is entirely a valuation argument, not a quality argument — and you have to hold both thoughts simultaneously. The business is structurally challenged: a legacy portfolio of off-patent drugs facing relentless price compression, a commoditized generics division with no durable edge, and a capital base that was assembled at peak acquisition multiples and has been destroying accounting value ever since. None of that is in dispute. What is in dispute is whether the free cash generation that sits quietly underneath all that GAAP carnage is being fairly compensated. The FCF yield signals the market is pricing a distressed outcome that the cash economics don't yet support, and if debt paydown continues on its current trajectory, a meaningful re-rating happens before the revenue erosion catches up. Where the business is heading is a slow, managed contraction with pockets of optionality — Japan launches, the biosimilar residual, emerging markets incremental growth — that won't reverse the secular decline but may slow it enough to make the cash harvesting thesis work. The 2026 cost program is real and the sequencing (debt first, buybacks second) is the right capital allocation discipline for this situation. The question is whether 'stabilization' turns into genuine stasis or whether the erosion accelerates as Chinese generics manufacturers mature and VBP sweeps into more product categories. The single most dangerous scenario is a refinancing event that forces management's hand at the wrong moment in the credit cycle. Viatris carries a debt load that looks manageable against current FCF but leaves no room for error — an India manufacturing disruption, an accelerated China price reset, or a broad credit market tightening that reprices their obligation stack could force dilutive equity issuance or asset sales at distressed valuations, collapsing the very margin of safety that makes the current price interesting.